CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 52 enrolled
Drug / intervention
Nortriptyline +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03652870
NCT03652870Phase 3Completed
CompareCT.gov

A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease

University College, London·interventional·Posted Aug 29, 2018·Updated May 6, 2023

In Brief

A Phase 3 clinical trial evaluating Nortriptyline, Escitalopram, and 1 other intervention for Depression and Parkinson Disease. Completed, enrolled 52 participants across 1 site.

Detailed Summary

This is a randomised trial in a NHS setting, comparing the clinical effectiveness and cost-effectiveness of the selective serotonin reuptake inhibitor, escitalopram, and of the tricyclic antidepressant, nortriptyline, to placebo, undertaken in a real-life setting in addition to standard psychological care for the treatment of patients with depression in Parkinson's disease. Participants will be randomly allocated 1:1:1 to receive escitalopram or nortriptyline or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Parkinson Disease
CountriesUnited Kingdom
CollaboratorsLondon North West Healthcare NHS Trust, King's College London, University Hospital Plymouth NHS Trust, NHS Lothian

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 29, 2018
Enrollment StartMar 5, 2021
Primary CompletionJan 23, 2023
Study CompletionApr 30, 2023
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.8 years ago

Interventions

Nortriptylinedrug

A medication used to treat conditions such as depression

Escitalopramdrug

A medication used to treat conditions such as depression

Placebodrug

Lactose and magnesium stearate tablet to be used as a placebo.